RIPK1 and RIPK3 have been shown to form necrosomes, phosphorylate downstream MLKL, and activate MLKL-mediated necroptosis in multiple neurodegenerative diseases, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), Gaucher’s disease (GD), and Alzheimer’s disease (AD) [21, 63]. This evidence concerns the gene MLKL and myeloid sarcoma.